Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Long-Term Investments (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Long-Term Investments for 5 consecutive years, with $128.1 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 15.81% to $128.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $128.1 million through Dec 2025, down 15.81% year-over-year, with the annual reading at $128.1 million for FY2025, 15.81% down from the prior year.
  • Long-Term Investments hit $128.1 million in Q4 2025 for Krystal Biotech, down from $133.1 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $152.1 million in Q4 2024 to a low of $4.6 million in Q4 2022.
  • Historically, Long-Term Investments has averaged $66.3 million across 5 years, with a median of $62.0 million in 2023.
  • Biggest five-year swings in Long-Term Investments: tumbled 92.82% in 2022 and later surged 1537.67% in 2024.
  • Year by year, Long-Term Investments stood at $64.4 million in 2021, then crashed by 92.82% to $4.6 million in 2022, then surged by 1240.71% to $62.0 million in 2023, then soared by 145.53% to $152.1 million in 2024, then dropped by 15.81% to $128.1 million in 2025.
  • Business Quant data shows Long-Term Investments for KRYS at $128.1 million in Q4 2025, $133.1 million in Q3 2025, and $138.8 million in Q2 2025.